Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial.

Mavoko, HM; Nabasumba, C; da Luz, RI; Tinto, H; D'Alessandro, U; Kambugu, A; Baraka, V; Rosanas-Urgell, A; Lutumba, P; Van Geertruyden, JP; (2016) Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. The Lancet Global health. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-109X(16)30236-4

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S2214-109X(16)30236-4

Abstract

Share

Download

Filename: Efficacy and safety of re-treatment_GOLD VoR.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar